Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Jim Van Meerten

NeoGenomics Stock Just Turned Its First Profit, Creating an Optimal Entry Point

  • NeoGenomics (NEO) is a leading cancer genetics diagnostics lab. Its stock recently hit a new 2-year high.
  • Shares are up more than 170% over the past 52 weeks.
  • NEO maintains a 100% “Buy” technical opinion from Barchart.
  • Analyst sentiment is predominantly bullish, with consensus price targets up to $35 and recent profitability marking a compelling entry point.

Today’s Featured Stock

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.